J&J’s LifeScan Gains FDA Clearance For Integration With WellDoc's BlueStar Diabetes Management System

21 December 2016

LifeScan, a subsidiary of J&J, won FDA clearance for wireless integration of its OneTouch Verio Flex blood glucose monitoring system with WellDoc‘s BlueStar diabetes management system.

This approval enables the OneTouch Verio Flex system to send blood glucose monitoring data wirelessly to the WellDoc Bluestar system, giving patients real-time health assessment and healthcare instructions based on their current state. The system also records the data for medical staff to keep up to speed on the patient’s health status and deliver better care.

Diabetes Stats
Diabetes UK state that diabetes is the fastest growing health threat of our generation having doubled since 1996 and that there are an estimated 4.5 million people with diabetes in the UK.

So What Does LifeScan’s WellDoc BlueStar Integration now mean for sufferers of diabetes and the medical profession?
The idea of the technology ifs of course to improve health. Clinical trials showed patients displayed a 1.9% decrease in glycated hemoglobin level over 12 months; 1.2% higher than without it. It’s also poised to give patients better control of their own self-monitoring and care and the need for less medical appointments.

LifeScans Valerie Asbury said in her press releases statement “Our partnership with WellDoc highlights our sustained commitment in helping to drive better health outcomes by building a more connected patient experience. Integrating digital solutions such as OneTouch Reveal mobile app and BlueStar will help patients self-manage their diabetes and create value for health care providers,”

Nicola Lawler, Head of marketing at Projectus Consulting